XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Operating expenses        
General and administrative $ 3,247,843 $ 3,185,451 $ 9,447,447 $ 9,167,560
Research and development 10,282,854 9,273,269 33,656,364 26,534,297
Total operating expenses 13,530,697 12,458,720 43,103,811 35,701,857
Operating loss (13,530,697) (12,458,720) (43,103,811) (35,701,857)
Other income (expenses)        
Grant income 25,000
Research and development incentive income 564,842 682,432 2,048,113 2,328,675
Interest income, net 1,827,945 229,917 4,560,784 242,405
Other financing expense (964,344)
Foreign exchange (loss) gain (101,066) (732,549) 146,239 (408,541)
Total other income, net 2,291,721 179,800 5,815,792 2,162,539
Net loss before provision for income taxes (11,238,976) (12,278,920) (37,288,019) (33,539,318)
Income tax expense, current (41,000) (88,421) (70,954) (148,201)
Net loss and comprehensive loss $ (11,279,976) $ (12,367,341) $ (37,358,973) $ (33,687,519)
Net Loss per share        
Basic and diluted $ (0.14) $ (0.16) $ (0.47) $ (0.44)
Weighted average number of shares outstanding        
Basic and diluted $ 80,875,235 $ 77,442,236 $ 79,051,038 $ 76,561,940